CNS Pharmaceuticals Names Rami Levin as CEO in Leadership Transition

Houston, TX, December 17, 2025 (ACCESS Newswire) -- CNS Pharmaceuticals announced a CEO transition, with industry veteran Rami Levin appointed President and Chief Executive Officer, effective January 1, 2026, following the departure of John Climaco. Levin brings nearly three decades of global leadership experience across oncology, neurology, rare diseases, and cell and gene therapy, including scaling organizations, advancing late-stage programs, and raising capital. The board highlighted Levin’s ability to guide companies through critical inflection points as CNS advances its pipeline, including TPI 287, toward its next phase of growth.

Read full article here.